Skip to main content Skip to main navigation menu Skip to site footer
Reumatismo - The Italian Journal of Rheumatology

Editor-in-Chief: M.A. Cimmino, Genova, Italy | eISSN 2240-2683

  • About the Journal
  • Publication Ethics
  • Editorial Board
  • Current Issue
  • Early Access
  • Archives
  • Special Issues
    • Overview
  • Register
  • Login
  • Search
  • Contacts
  • News
1.0
Impact Factor 2024
1.7
CiteScore 2024
1.0
Impact Factor 2024
1.7
CiteScore 2024
Submit
an article
  1. Home /
  2. Search

Search

Advanced filters
Published After
Published Before

Search Results

##search.searchResults.foundPlural##
  • Antibodies to extractable nuclear antigens (ENAS) in systemic lupus erythematosus patients: correlations with clinical manifestations and disease activity

    Y. Emad, T. Gheita, H. Darweesh, P. Klooster, R. Gamal, H. Fathi, N. El-Shaarawy, M. Gamil, M. Hawass, R.M. El-Refai, H. Al-Hanafi, S. Abd-Ellatif, A. Ismail, J. Rasker
    85-91
    06-07-2018
    https://doi.org/10.4081/reumatismo.2018.1027
    2911
    PDF: 1644
  • PO:15:220 | Outcomes of extra renal flares in systemic lupus erythematosus: longitudinal analysis of a monocentric cohort Marco Oliva1, Giorgia Capozzo1, Giancarlo Cascarano1, Chiara Cardelli1, Dina Zucchi1, Angela Elia1, Elena Elefante2, Viola Signorini2, Chiara Stagnaro2, Chiara Tani1, Marta Mosca1. | 1Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy; 2Rheumatology Unit, AOUP, Pisa, Italy.

    Società Italiana di Reumatologia
    25-11-2025
    https://doi.org/10.4081/reumatismo.2025.2040
    138
  • PO:14:193 | Dapirolizumab Pegol Demonstrated Significant Improvement in Systemic Lupus Erythematosus Disease Activity: Efficacy and Safety Results of a Phase 3 Trial Megan EB Clowse1, Marta Mosca2, David A Isenberg3, Joan T Merrill4, Thomas Dörner5, Michelle Petri6, Edward M Vital7|8, Eric F Morand9, Teri Jimenez10, Stephen Brookes11, Janine Gaiha-Rohrbach12, Christophe Martin13, Annette Nelde14, Christian Stach15 | 1Duke University - Division of Rheumatology and Immunology Durham, USA; 2University of Pisa - Rheumatology Unit, Department of Clinical and Experimental Medicine Pisa, Italy; 3University College London - Department of Ageing, Rheumatology and Regenerative Medicine, Division of Medicine London, United Kingdom; 4Oklahoma Medical Research Foundation Oklahoma City, USA; 5Charité Universitätsmedizin Berlin - Department of Medicine/Rheumatology and Clinical Immunology Berlin Germany; 6Johns Hopkins University School of Medicine Baltimore, USA; 7University of Leeds - Leeds Institute of Rheumatic and Musculoskeletal Medicine Leeds, United Kingdom; 8Leeds Teaching Hospitals NHS Trust - NIHR Leeds Biomedical Research Centre Leeds, United Kingdom; 9Monash University - Centre for Inflammatory Diseases Melbourne, Australia; 10UCB Raleigh, USA; 11Biogen Maidenhead, United Kingdom; 12Biogen Cambridge, USA; 13UCB Slough, United Kingdom; 14Biogen Baar, Switzerland; 15UCB Monheim am Rhein, Germany

    Società Italiana di Reumatologia
    18-03-2026
    https://doi.org/10.4081/reumatismo.2025.2318
    45
  • PO:14:197 | Safety of biologic and conventional immunosuppressants in an Italian cohort of patients with systemic lupus erythematosus: a longitudinal analysis from the Lupus Italian Registry pharmacoepidemiologic study promoted by the Italian Society of Rheumatology Davide Rozza1, Carlo Alberto Scirè1|2, Paola Conigliaro3, Giacomo Emmi4, Laura Coladonato6, Salvatore Scarpato7, Luca Iaccarino8, Serena Guiducci9, Giulia Pazzola10, Francesca Romana Spinelli11, Micol Frassi12, Ilaria Cavazzana12, Chiara Scirocco13, Valeria Orefice13, Immacolata Prevete13, Alessandra Bortoluzzi14, Marcello Govoni14, Elena Bartoloni15, Luca Moroni16, Giuseppe Alvise Ramirez16, Valentina Canti16, Giorgio Pettiti17, Maria Chiara Ditto18, Enrico Fusaro18, Marta Mosca19, Lorenzo Cavagna20, Fabrizio Conti11, Andrea Doria8, Gian Domenico Sebastiani13, Sperimentatori Gruppo Lire5 | 1Centro Studi della Società Italiana di Reumatologia, Milano; 2Dipartimento di Medicina e Chirurgia, Università degli Studi di Milano-Bicocca, Monza; 3Università di Roma Tor Vergata; 4Dipartimento di Scienze Mediche, Chirurgiche e della Salute, Università di Trieste; 5https://redcap.reumatologia.it/surveys/?s=LWL7WJM4KHDR97CC; 6Dip di Medicina di Precisione e Rigenerativa e area Jonica, Bari; 7Azienda Sanitaria Locale ASL Salerno; 8Università degli Studi di Padova; 9SOD Reumatologia, Dipartimento di Medicina Sperimentale e Clinica, Università degli Studi di Firenze; 10Arcispedale Santa Maria Nuova Reggio Emilia; 11Università degli Studi di Roma La Sapienza; 12Spedali Civili di Brescia; 13Azienda Ospedaliera San Camillo Forlanini, Roma; 14Azienda Ospedaliera Universitaria Sant'Anna, Ferrara; 15SC Reumatologia, Dipartimento di Medicina e Chirurgia, Università di Perugia; 16IRCCS Ospedale San Raffaele, Milano; 17Azienda Ospedaliera S. Croce e Carle, Cuneo; 18AOU Citta' della Salute e della Scienza di Torino; 19AOU Santa Chiara, Pisa; 20Università di Pavia, Italy

    Società Italiana di Reumatologia
    25-11-2025
    https://doi.org/10.4081/reumatismo.2025.2158
    147
  • PO:16:232 | Belimumab step-down dose spacing in patients with systemic lupus erythematosus in persistent clinical remission: experience from a multicentric cohort Alice Bartoletti1, Laura Giudice1, Lorenza Maria Argolini1|2, Giuseppe Alvise Ramirez3, Luca Moroni3, Tommaso Schioppo4, Chiara Bellocchi5|6, Annalaura Fasiello6, Lorenzo Beretta6, Lorenzo Dagna3, Roberto Caporali1, Maria Gerosa1. | 1UO Clinica Reumatologica, ASST Gaetano Pini CTO, Milano, Italy; 2UOC Medicina fisica e riabilitazione specialistica, ASST Gaetano Pini CTO, Milano, Italy; 3Unit of Immunology, Rheumatology, Allergy and Rare Diseases, IRCCS San Raffaele Hospital, Vita-Salute San Raffa Milano Italy; 4Medicina Generale II, Servizio di Reumatologia, Ospedale San Paolo, ASST Santi Paolo Carlo, Milano, Italy; 5Department of Clinical Sciences and Community Health, University of Milan, Dipartimeto di Eccellenza 2023-2027, Milano, Italy; 6Referral Centre for Systemic Autoimmune DIseases, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Milano, Italy

    Società Italiana di Reumatologia
    25-11-2025
    https://doi.org/10.4081/reumatismo.2025.2044
    167
  • PO:15:208 | Impact of disease control on organ damage accrual in patients with systemic lupus erythematosus with and extra-renal flares: a 12-month single-center longitudinal study Giorgia Capozzo1, Marco Oliva1, Giancarlo Cascarano1, Chiara Cardelli1, Dina Zucchi1, Chiara Stagnaro2, Viola Signorini2, Elena Elefante2, Chiara Tani1, Marta Mosca1. | 1Università di Pisa, Dipartimento di Medicina Clinica e Sperimentale, Pisa, Italy; 2Azienda Ospedaliero Universitaria Pisana, U.O. Reumatologia, Pisa, Italy.

    Società Italiana di Reumatologia
    25-11-2025
    https://doi.org/10.4081/reumatismo.2025.2037
    145
1 - 6 of 6 items
Make a Submission

authors

FOR AUTHORS
  • ARTICLE PROCESSING CHARGE
  • Guide for Authors
  • Benefits for Authors
  • How to write a scientific paper
  • How to write a Review article

reviewers

FOR REVIEWERS
  • Benefits for Reviewers
  • How to review
  • Thanks to Reviewers

Categories

    • Abstract Book
    • Oral Communications - Day 1
    • Posters - Day 1
    • Oral Communications - Day 2
    • Posters - Day 2
    • Oral Communications - Day 3

indexing

INDEXING
  • PubMed
  • Scopus
  • Web of Science
  • Google Scholar
  • OpenAlex
  • Scilit
  • DOAJ
  • Società Italiana di Reumatologia
  • Analytics

linkedin

Follow Reumatismo on

Vol. 78 No. 1 (2026)
The Italian Society for Rheumatology guidelines for the treatment of patients with rheumatoid arthritis and interstitial lung disease
Chiara Crotti et al.
10 November 2025
Vol. 78 No. 1 (2026)
From anatomy to therapy: the historical journey to cortisone
Ernesto Damiani et al.
19 November 2025
Vol. 78 No. 1 (2026)
Computed tomography of interstitial lung disease in systemic sclerosis: dataset and deep learning model for pulmonary lesion segmentation
Amir M. Vahdani et al.
25 February 2026
Vol. 78 No. 1 (2026)
Macrophage activation syndrome and rapidly progressive lung disease as life-threatening manifestations of anti-MDA5 antibody disease. A case report
Filippo Gozzi et al.
22 December 2025

Keywords

Reumatismo - The Italian Journal of Rheumatology

is the Official Journal of the Italian Society of Rheumatology (SIR). Founded in 1949. Published online by PAGEPress®, Pavia, Italy. All credits and honors to PKP for their OJS.

pISSN: 0048-7449
eISSN: 2240-2683

Info

  • About
  • Editorial Board
  • News
  • Advertising

Info Submission

  • Submission
  • Guidelines For Authors
Themes by Openjournaltheme.com

© PAGEPress 2008-2026    •    PAGEPress® is a registered trademark property of PAGEPress srl, Italy    •    VAT: IT02125780185    •    Privacy